$PGEN

Lehr Donald P. sold $127K of PGEN

Lehr Donald P. (Chief Legal Officer) sold 29,131 shares of PRECIGEN, INC. (PGEN) at $4.36 ($0.13M total) on 2026-05-28.

Original reporting
SEC EDGAR · Lehr Donald P.
Published Jun 1, 2026, 8:26 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 1, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PGEN
Neutral
medium confidence
Mentioned
$PGEN
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PGENNeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on insider behavior (open-market sale by CLO) but lacks any new operational or clinical development that would re-rate the company’s fundamentals.

02

Market read

Traders may monitor for follow-on insider activity or correlate with upcoming corporate catalysts, but the filing alone is unlikely to drive a major repricing.

03

What to watch

No context is given on total insider holdings changes, prior sales cadence, or whether other officers/board members also sold/bought around the same period.

Relevance 6/10Novelty 6/10Timing: Filed 2026-06-01; reflects sale executed 2026-05-28.

Background

The article is an SEC Form 4 disclosure of an insider’s transaction in Precigen common stock.

Company-level read

Ticker impact

$PGENNeutralMedium confidence
Context

Pre-arranged 10b5-1 plan was not used; Chief Legal Officer Donald Lehr sold 29,131 shares of Precigen at $4.36 on 2026-05-28.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to sentiment/flow effects around the filing date.

Evidence & confidence

The filing is an SEC Form 4 insider transaction with disclosed sale size and price, but no accompanying corporate event (earnings, trial result, deal, or guidance change) is provided.

Market effects

Limited read-through to biotech/clinical pipeline peers; this is company-specific insider activity without sector-wide catalyst.

None indicated; US-listed microcap/small-cap flow only.

None indicated.

Counterpoint

The sale may be routine liquidity/compensation-related and does not necessarily signal negative fundamentals, especially without evidence of other concurrent insider selling.

Key entities

  • PRECIGEN, INC.

    Subject of the insider transaction disclosure (Form 4).

  • Donald P. Lehr

    Chief Legal Officer who sold shares; transaction reported as open-market sale without a pre-arranged 10b5-1 plan.

Related articles

$PGENMed

PRECIGEN, INC. (PGEN): Results of Operations and Financial Condition

PRECIGEN, INC. (PGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 dp251262_ex9901.htm EXHIBIT 99.1 Exhibit 99.1 Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth · PAPZIMEOS ® net revenue of $53.1 million in the second quarter of 2026, more than double the prior quarter, reflec

$PGENMedAI 9/10

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen (Nasdaq: PGEN) reported updated long-term durability data for PAPZIMEOS (zopapogene imadenovec-drba) in adults with recurrent respiratory papillomatosis. According to the company, 15 of 18 complete responders (83%) had ongoing complete responses for at least 36 months as of April 30, 2026, with 5 beyond 4 years; median duration not yet reached and no new safety events were observed. The FDA granted seven-year orphan drug market exclusivity.

$PGENMedAI 9/10

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen (Nasdaq: PGEN) reported updated long-term durability data for PAPZIMEOS (zopapogene imadenovec-drba) in adults with recurrent respiratory papillomatosis (RRP), presented at the 2026 ASCO meeting. As of April 30, 2026, 15 of 18 complete responders (83%) had ongoing complete responses for ≥36 months without additional RRP treatment; 5 responders had responses beyond 4 years. Precigen said no new adverse safety events were observed. The FDA granted PAPZIMEOS seven-year orphan drug market e